Renal Acidosis - VALOR / Preserve-Transplant - Prof. Nilufar Mohebbi, Prof. Navdeep Tangri

Dr. Nilufar Mohebbi and Dr. Navdeep Tangri discuss topical approaches for the treatment of renal acidosis, focussing upon their phase 3 PRESERVE-Transplant and VALOR-CKD studies, which have been published recently.
Dr. Nilufar Mohebbi is Physician for General Internal Medicine and Nephrology at the NephroCare Dialysis Centre Zurich-City, and Professor at Zurich Kidney Center at the University of Zurich. She has done basic science research on tubular diseases including renal tubular acidoses at the Universities of Berlin and Zurich, which stimulated her to initiate the PRESERVE-Transplant study in Switzerland.
Dr. Tangri is an attending physician and Professor in the Division of Nephrology, Department of Internal Medicine and Department of Community Health Sciences in the Rady Faculty of Health Sciences at the University of Manitoba. Dr. Tangri’s research program focusses on improving clinical decision making for patients with or at risk for chronic kidney disease,, and on designing and conducing large observational studies and randomized trials in CKD, including VALOR-CKD:
The interview was recorded on June 24th, 2024.
Moderators: Prof. Dr. Marcus Säemann (Vienna, Austria) and Prof. Dr. Gunnar Heine (Frankfurt, Germany).
Articles discussed:
Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.
Mohebbi N, Ritter A, Wiegand A, Graf N, Dahdal S, Sidler D, Arampatzis S, Hadaya K, Mueller TF, Wagner CA, Wüthrich RP
Lancet 2023
doi: 10.1016/S0140-6736(22)02606-X
VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis.
Tangri N, Mathur VS, Bushinsky DA, Klaerner G, Li E, Parsell D, Stasiv Y, Walker M, Wesson DE, Wheeler DC, Perkovic V, Inker LA.
J Am Soc Nephrol 2024
doi: 10.1681/ASN.0000000000000292
Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial.
Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, Klaerner G, Bushinsky DA.
Lancet 2019
doi: 10.1016/S0140-6736(18)32562-5
Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension.
Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, Klaerner G, Bushinsky DA.
Lancet 2019
doi: 10.1016/S0140-6736(19)31388-1
Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis.
Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, Chodick G, Collins AJ, Djurdjev O, Elley CR, Evans M, Garg AX, Hallan SI, Inker LA, Ito S, Jee SH, Kovesdy CP, Kronenberg F, Heerspink HJ, Marks A, Nadkarni GN, Navaneethan SD, Nelson RG, Titze S, Sarnak MJ, Stengel B, Woodward M, Iseki K; CKD Prognosis Consortium.
JAMA 2016
doi: 10.1001/jama.2015.18202
A predictive model for progression of chronic kidney disease to kidney failure.
Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS
JAMA 2011
doi: 10.1001/jama.2011.451
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.
Kidney Int 2024
doi: 10.1016/j.kint.2023.10.018